<DOC>
	<DOCNO>NCT01414608</DOCNO>
	<brief_summary>This randomized phase III trial study well give cisplatin radiation therapy together without carboplatin paclitaxel work treat patient locally advanced cervical cancer . Drugs use chemotherapy , cisplatin , carboplatin , paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . External radiation therapy use high-energy x ray kill tumor cell . Internal radiation use radioactive material place directly near tumor kill tumor cell . It yet know whether give cisplatin external internal radiation therapy together carboplatin paclitaxel kill tumor cell .</brief_summary>
	<brief_title>Cisplatin Radiation Therapy With Without Carboplatin Paclitaxel Patients With Locally Advanced Cervical Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine addition adjuvant chemotherapy standard cisplatin-based chemoradiation improve overall survival . SECONDARY OBJECTIVES : I . To determine progression-free survival rate . II . To determine acute long-term toxicity . III . To determine pattern disease recurrence . IV . To determine association radiation protocol compliance outcome . V. To determine patient quality life , include psycho-sexual health . TERTIARY OBJECTIVES : I . To determine association result follow-up positron emission tomography ( PET ) scan perform 4-6 month post completion chemoradiation outcomes patient trial . II . To determine biological predictor patient ' outcome base translational laboratory study blood tissue specimen . OUTLINE : This multicenter study . Patients stratify accord pelvic common iliac nodal involvement ( yes v ) , requirement extended-field radiotherapy treatment ( yes v ) , International Federation Gynecology Obstetrics ( FIGO ) stage ( IB/IIA vs IIB v IIIB/IVA ) , age ( &lt; 60 year age v &gt; = 60 year age ) , hospital/site . Patients randomize 1 2 treatment arm . ARM I : Patients receive cisplatin intravenously ( IV ) 60-90 minute day 1 , 8 , 15 , 22 , 29 . Patients also undergo external-beam radiation therapy daily , 5 day week , approximately 5 week . Patients undergo high-dose rate , pulsed-dose rate , low-dose rate intracavitary brachytherapy . ARM II : Patients receive cisplatin undergo external-beam radiation brachytherapy arm I . Beginning 4 week later , patient also receive adjuvant chemotherapy comprise paclitaxel IV 3 hour carboplatin IV 1 hour day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients may undergo baseline tumor biopsy blood collection future correlative study . Patients complete European Organization Research Treatment Cancer ( EORTC ) Core questionnaire ( QLQ-C30 ) , EORTC cervix cancer module ( CX24 ) , ovarian cancer module ( OV28 ) , Sexual function-Vaginal Changes Questionnaire ( SVQ ) questionnaires baseline , , completion study treatment . After completion study therapy , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Adenosquamous</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Eligible patient locally advanced cervical cancer suitable primary treatment chemoradiation curative intent , addition : Histological diagnosis squamous cell carcinoma , adenocarcinoma , adenosquamous cell carcinoma cervix FIGO 2008 stage IB1 &amp; node positive , IB2 , II , IIIB , IVA disease Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Histological diagnosis squamous cell carcinoma , adenocarcinoma adenosquamous cell carcinoma cervix White blood cell ( WBC ) &gt; = 3.0 x 10^9/L Absolute neutrophil count ( ANC ) &gt; = 1.5 x 10^9/L Platelet count &gt; = 100 x 10^9/L Bilirubin = &lt; 1.5 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 x ULN Creatinine = &lt; ULN ( Common Toxicity Criteria [ CTC ] Grade 0 ) OR calculate creatinine clearance ( CockcroftGault Formula ) &gt; = 60 mL/min OR &gt; = 50 mL/min ethylenediaminetetraacetic acid ( EDTA ) creatinine clearance Written inform consent Any previous pelvic radiotherapy Paraaortic nodal involvement level common iliac node L3/L4 ( biopsy proven , PET positive , &gt; = 15 mm shortaxis diameter compute tomography [ CT ] ) FIGO 2008 stage IIIA disease Patients assess presentation require interstitial brachytherapy treatment Patients bilateral hydronephrosis unless least one side stented renal function fulfills require inclusion criterion Previous chemotherapy tumor Evidence distant metastasis Prior diagnosis Crohn disease ulcerative colitis Peripheral neuropathy &gt; = grade 2 ( per Common Terminology Criteria Adverse Events [ CTCAE ] v. 4 ) Patients undergone previous hysterectomy hysterectomy part initial cervical cancer therapy Patients invasive malignancy , exception nonmelanoma skin cancer situ melanoma , ( ) evidence cancer present within last 5 year Patients pregnant lactate Any contraindication use cisplatin , carboplatin , paclitaxel chemotherapy Serious illness medical condition precludes safe administration trial treatment include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Human immunodeficiency virus ( HIV ) positive</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>